ACADIA Pharmaceuticals (NASDAQ:ACAD) and BioXcel Therapeutics (NASDAQ:BTAI) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, risk, valuation, profitability and institutional ownership.
Profitability
This table compares ACADIA Pharmaceuticals and BioXcel Therapeutics' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
|---|
| ACADIA Pharmaceuticals | -63.92% | -40.35% | -34.72% |
| BioXcel Therapeutics | N/A | -74.22% | -64.31% |
Risk and Volatility
ACADIA Pharmaceuticals has a beta of 1.44, indicating that its share price is 44% more volatile than the S&P 500. Comparatively, BioXcel Therapeutics has a beta of 1.31, indicating that its share price is 31% more volatile than the S&P 500.
Institutional & Insider Ownership
93.5% of ACADIA Pharmaceuticals shares are held by institutional investors. Comparatively, 48.7% of BioXcel Therapeutics shares are held by institutional investors. 27.7% of ACADIA Pharmaceuticals shares are held by insiders. Comparatively, 9.4% of BioXcel Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Earnings & Valuation
This table compares ACADIA Pharmaceuticals and BioXcel Therapeutics' revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
|---|
| ACADIA Pharmaceuticals | $339.08 million | 9.64 | $-235,260,000.00 | ($1.60) | -12.77 |
| BioXcel Therapeutics | N/A | N/A | $-32,970,000.00 | ($2.02) | -17.36 |
BioXcel Therapeutics has lower revenue, but higher earnings than ACADIA Pharmaceuticals. BioXcel Therapeutics is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of current ratings and recommmendations for ACADIA Pharmaceuticals and BioXcel Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
|---|
| ACADIA Pharmaceuticals | 0 | 12 | 7 | 0 | 2.37 |
| BioXcel Therapeutics | 0 | 0 | 11 | 0 | 3.00 |
ACADIA Pharmaceuticals presently has a consensus price target of $32.7647, indicating a potential upside of 60.38%. BioXcel Therapeutics has a consensus price target of $101.8182, indicating a potential upside of 190.33%. Given BioXcel Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe BioXcel Therapeutics is more favorable than ACADIA Pharmaceuticals.
Summary
ACADIA Pharmaceuticals beats BioXcel Therapeutics on 7 of the 13 factors compared between the two stocks.
